Relmada Therapeutics, Inc. RLMD Business development
Business development at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:BusinessDevelopment.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s business development.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s business development?
- Relmada Therapeutics, Inc. (RLMD) reported business development of $200M in Q1 2026.
- What does business development mean?
- Expenditures or investments dedicated to strategic growth initiatives, such as licensing agreements, partnerships, or the acquisition of intellectual property. This metric indicates the company's commitment to expanding its pipeline or market reach through external collaboration.